WuXi XDC
Hong Kong / Shanghai, China (+ Singapore facility in development)
Program data pending ClinicalTrials.gov matching
—
Not Assessed
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesADC, Bioconjugates, Antibody intermediates, Chemical payload-linker synthesis, ADC drug product fill-finish
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
—
Insufficient financial data. Score requires company profile or SEC filings.
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
—
Insufficient capacity data. Score requires company profile with manufacturing site information.
Recent Press10 articles
Broad modality coverage (5 modalities)
Recent News 10 articles
Celltrion, WuXi XDC to develop new antibody-drug conjugates - The Korea Economic Daily Global Edition
WuXi XDC issues positive profit alert, to acquire BioDlink in bid to strengthen ADC CDMO lead - TradingView
WuXi’s ADC CDMO stages $500m IPO - BioProcess International
Contractors WuXi Bio, WuXi XDC eye continued growth after logging solid performances in 2024 - Fierce Pharma
WuXi XDC completes construction of Singapore bioconjugation site - BioProcess International
WuXi XDC Named the Winner of "Best CDMO" and "Best CRO" at 2025 World ADC Awards - PR Newswire
WuXi XDC raises $520m in IPO; eyes Singapore and China expansions - BioProcess International
WuXi XDC Established as New CDMO - Genetic Engineering and Biotechnology News
WuXi Biologics breaks ground on microbial production plant in China - Fierce Pharma
Chinese CDMO seeks to consolidate leadership in ADC space - The Pharma Letter
Represent this organization? Contact us to verify or update this profile.